Training Example: IMBRUVICA (ibrutinib) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H1]
[H2] IMBRUVICA® has helped many adults with CLL/SLL live longer
In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*Here's to more time together and the opportunity to keep doing what you love.Here's to the life in your yearsLearn More
[H2] Eddie talked to his doctor about side effects
They discussed options and if a dose adjustment was appropriate for him.Eddie, a real IMBRUVICA® patient with CLLWatch Eddie’s Story
[H2] Experience matters
See what a healthcare professional has to say about treating CLL with IMBRUVICA® (ibrutinib).Lisa Nodzon, PhD, ARNP, AOCNPHear a Professional PerspectiveChoose indicationCLL/SLLAdults with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWMAdults with Waldenström's MacroglobulinemiacGVHDPreviously Treated Chronic Graft Versus Host Disease in Adults and ChildrenIn one clinical trial of 269 people aged 65 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.Receive one-on-one support plus financial and educational resourcesCall the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.† New patients: Ask your doctor how to get a free Patient Starter Kit.Explore SupportHere’s to saving on IMBRUVICA®You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply‡ Medicare Part D Members: What you need to know in 2025Explore Savings†IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.‡Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.Reference: 1. IMBRUVICA® (ibrutinib) Prescribing Information.

[IMG: Affording IMBRUVICA® (ibrutinib)]
[IMG: Affording IMBRUVICA® (ibrutinib)]
[H1] AffordingIMBRUVICA® (ibrutinib)
HomeAffording IMBRUVICA®PrintShare
[H2] Coverage and Cost
[H3] 2025 Medicare Part D Benefits Updates for IMBRUVICA® Patients
UPDATE #1
You Could Be Paying Less for IMBRUVICA® With Capped Out-of-Pocket (OOP) Costs
Starting January 1, 2025, patients’ OOP costs will be limited to $2,000 annually for all covered Medicare Part D prescription drugs, including IMBRUVICA®.1UPDATE #2
Spread Out Your Payments with the Medicare Prescription Payment Plan (MPPP)
You may sign up for a new program, the MPPP, which would spread the OOP costs for your prescription throughout the year into monthly payments with no fees or interest. Once enrolled, you will be billed directly every month from your plan and pay $0 at the pharmacy.2Patients receiving foundation or charity assistance should NOT enroll in the MPPP.Contact your insurance provider or download the Patient Education Brochure for more information.References: 1. Explaining the prescription drug provisions in the Inflation Reduction Act. KFF. January 24, 2023. Accessed September 18, 2024. https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act 2. Medicare Prescription Payment Plan. CMS. February 29, 2024. Accessed September 18, 2024. https://www.cms.gov/files/document/medicare-prescription-payment-plan-final-part-one-guidance.pdfWhen you have support, such as help understanding your insurance coverage and potential ways to pay for IMBRUVICA®, you may feel more confident during treatment. The IMBRUVICA® By Your Side patient support program is here to help answer some of your questions about the financial aspects of taking IMBRUVICA®.*Learn more about your insurance coverage and potential financial support options. Call the IMBRUVICA® By Your Side Nurse Support Line at1-888-YourSide (1-888-968-7743)Monday through Friday, 8:00 AM to 8:00 PM ETIMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have.
[H2] IMBRUVICA® Copay Card
If you have commercial insurance, you could get IMBRUVICA® for as little as$0per prescription††Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvicacom/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.Enroll for the IMBRUVICA® Copay Card
[H2] Understanding Insurance
Most people have healthcare and prescription drug insurance coverage through a private organization or the federal or state government.Commercial (or private) insuranceCommercial insurance is coverage you have through your employer, or that you’ve purchased from a private insurance company or the health insurance marketplace. If you have commercial insurance, you may be eligible to pay as little as $0 per prescription of IMBRUVICA® with the IMBRUVICA® Copay Card.Government insuranceYou may have insurance coverage through the federal government or the state where you live. Common plans include Medicare, Medicare Part D, Medicaid, VA, and TRICARE.If you have a government insurance plan, potential financial support for IMBRUVICA® may be available through an independent foundation.
[H2] Other Resources
[H3] MyAbbVie Assist
We believe that people who need our medicines should be able to get them. That's why myAbbVie Assist provides free AbbVie medicine to qualifying patients. 1-800-222-68858 am to 5 pm (CT)VISIT
[H3] Want to know more about Medicare Part D coverage for IMBRUVICA®?
Download Here
[H2] The IMBRUVICA® By Your Side patient support program is with you along the way.
Explore Support Options

[H2] IMBRUVICA® has helped many adults with CLL/SLL live longer
In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*Here's to more time together and the opportunity to keep doing what you love.Here's to the life in your yearsLearn More
[H2] Eddie talked to his doctor about side effects
They discussed options and if a dose adjustment was appropriate for him.Eddie, a real IMBRUVICA® patient with CLLWatch Eddie’s Story
[H2] Experience matters
See what a healthcare professional has to say about treating CLL with IMBRUVICA® (ibrutinib).Lisa Nodzon, PhD, ARNP, AOCNPHear a Professional PerspectiveCLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma.In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.
[H2] Welcome to a different way of treating CLL/SLL
IMBRUVICA® works differently from chemotherapy. This once-daily, oral medication blocks a protein in B cells called Bruton's tyrosine kinase, or BTK. For more complete information on how IMBRUVICA® works and the possible side effects, go to the How Does IMBRUVICA® Work? section.1
[H2] With IMBRUVICA®, there’s a once-daily oral treatment option available to treat CLL/SLL1
IMBRUVICA® is a prescription medicine used to treat adults with:Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletionIt is not known if IMBRUVICA® is safe and effective in children.Receive one-on-one support plus financial and educational resourcesCall the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.†Explore SupportHere’s to saving on IMBRUVICA®You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply‡ Medicare Part D Members: What you need to know in 2025Explore SavingsThinking about treatment with IMBRUVICA®?Sign up today to receive the latest information and helpful resources.Register Now†IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Johnson & Johnson and its affiliates and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.‡Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. National Institutes of Health. BTK gene. Accessed July 29, 2025. https://medlineplus.gov/genetics/gene/btk/

[H2] Here's to making lasting memories
Once-daily IMBRUVICA® (ibrutinib) is the first FDA-approved therapy for adults with WMWM=Waldenström's macroglobulinemia.
[H2] When Denis' WM symptoms got worse...
He talked to his doctor about his treatment options.Watch Denis’ Story
[H2] Receive one-on-one support plus financial and educational resources
Call the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.*Explore Support
[H2] Welcome to a different way of treating WM
Starting treatment with IMBRUVICA® for your WM is an important time in your journey. This website will help you learn more about your condition and how IMBRUVICA® can help.IMBRUVICA® works differently from chemotherapy. For more information on how IMBRUVICA® works, go to the How Does IMBRUVICA® Work? section.1
[H2] With IMBRUVICA®, there’s a once-daily oral treatment option available to treat adults with WM1
It is not known if IMBRUVICA® is safe and effective in children.Receive one-on-one support plus financial and educational resourcesCall the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.*Explore SupportHere’s to saving on IMBRUVICA®You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply† Medicare Part D Members: What you need to knowExplore SavingsIMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Johnson & Johnson and its affiliates and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.†Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side-copay-card or call 1-888-968-7743 for additional information. To learn about AbbVie's privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.Reference: 1. IMBRUVICA® (ibrutinib) Prescribing Information.